Last $5.25 USD
Change Today -0.04 / -0.76%
Volume 59.8K
ONTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

onconova therapeutics inc (ONTX) Snapshot

Open
$5.29
Previous Close
$5.29
Day High
$5.33
Day Low
$5.09
52 Week High
10/4/13 - $31.13
52 Week Low
06/5/14 - $4.10
Market Cap
113.9M
Average Volume 10 Days
72.0K
EPS TTM
$-3.66
Shares Outstanding
21.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCONOVA THERAPEUTICS INC (ONTX)

Related News

No related news articles were found.

onconova therapeutics inc (ONTX) Related Businessweek News

No Related Businessweek News Found

onconova therapeutics inc (ONTX) Details

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company’s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.

64 Employees
Last Reported Date: 03/20/14
Founded in 1998

onconova therapeutics inc (ONTX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $742.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $347.9K
President of Research and Development
Total Annual Compensation: $359.0K
Senior Vice President of Product Development
Total Annual Compensation: $424.8K
Compensation as of Fiscal Year 2013.

onconova therapeutics inc (ONTX) Key Developments

Onconova Therapeutics, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:05 PM

Onconova Therapeutics, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:05 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: Ramesh Kumar, Co-Founder, Chief Executive Officer, President and Director.

Onconova Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Onconova Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $125,000 against $591,000 a year ago. Loss from operations was $16,764,000 against $12,573,000 a year ago. Net loss applicable to common stockholders was $16,753,000 or $0.77 per basic and diluted share against $13,594,000 or $5.21 per basic and diluted share a year ago. For the six months, the company reported revenue of $572,000 against $1,707,000 a year ago. Loss from operations was $35,497,000 against $27,559,000 a year ago. Net loss applicable to common stockholders was $35,432,000 or $1.64 per basic and diluted share against $29,458,000 or $11.29 per basic and diluted share a year ago.

Onconova Therapeutics, Inc. to Report Q2, 2014 Results on Aug 13, 2014

Onconova Therapeutics, Inc. announced that they will report Q2, 2014 results at 6:27 PM, GMT Standard Time on Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTX:US $5.25 USD -0.04

ONTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTX.
View Industry Companies
 

Industry Analysis

ONTX

Industry Average

Valuation ONTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.7x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCONOVA THERAPEUTICS INC, please visit www.onconova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.